Core Insights - Artelo Biosciences is entering the ophthalmology market with a clinical study for ART27.13 targeting glaucoma patients, backed by Glaucoma UK and HSC R&D Division, with first enrollment expected in Q2 2026 [1][2][7] Industry Overview - The global glaucoma market was valued at USD 9.46 billion in 2025 and is projected to reach USD 16.31 billion by 2033, growing at a compound annual growth rate of 7.05% [2] - Approximately 145.9 million people were affected by glaucoma in 2021, expected to rise to 166 million by 2026 [2] - In the U.S., 4.2 million adults had glaucoma in 2022, projected to increase to 6.3 million by 2050 [2] Company Strategy - Artelo's entry into the glaucoma space represents a significant diversification of its pipeline without requiring dilutive equity financing [1][7] - The investigator-sponsored trial model allows Artelo to maintain strategic control and data rights while reducing financial burdens [7] Product Differentiation - ART27.13 is a synthetic cannabinoid receptor agonist that modulates intraocular pressure (IOP) without central nervous system side effects, targeting CB2 receptors for anti-inflammatory and neuroprotective effects [5][6] - Current standard treatments primarily focus on lowering IOP, leaving neuroprotective needs unaddressed, highlighting the opportunity for ART27.13 [4][5] Clinical Development - The study will be led by Professor Augusto Azuara-Blanco at Queen's University Belfast, focusing on the effects of ART27.13 on IOP [7] - The cross-over study design enhances statistical power and reduces required enrollment numbers [7] Pipeline and Intellectual Property - ART27.13 is not limited to glaucoma; it has shown positive interim Phase 2 data in cancer-related anorexia, indicating its broader therapeutic potential [8] - Artelo has received a Notice of Allowance from the European Patent Office for ART27.13, extending patent protection through December 2041 [9] Key Milestones - First patient enrollment in the glaucoma pilot study is expected in Q2 2026 [10] - Ongoing Phase 2 CAReS trial for cancer-related anorexia [10] - European patent protection for ART27.13 commercial formulation through 2041 [10]